The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery

Yonsei University

Status and phase: Completed; Phase 4

Conditions: Coronary Artery Occlusive Disease

Treatments: Drug: 6% hydroxyethyl Stach 130/0.4

Study type: Interventional

Funder types: Other

Identifiers

NCT01051206

4-2009-0057

Details and patient eligibility

About

HES 130/0.4 significantly solution will not affect on coagulation and blood loss in patients medicated with antiplatelet agents prior to off-pump coronary bypass surgery (OPCAB).

Enrollment: 106 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Eighty patients undergoing OPCAB, who were exposed to anti platelet agents until 5 days prior to surgery were randomly allocated to infuse HES 130/0.4 up to 30 ml/kg and followed crystalloid infusion or infuse crystalloid only during perioperative period,

Exclusion criteria

Patient who has

• Valvular disease of heart
• MI within 3 months,patient under 40% of left ventricle preoperative output
• left main artery stenosis
• anemia (hemoglobin < 12 g/dl), coagulopathy (Platelet < 100/nl, activated partial thromboplastin time, aPTT) > 80sec, serum creatinine > 1.2 mg/dl, respiratory disease(asthma, COPD, PaO2 < 70 mmHg, pulmonary hypertension or pulmonary edema, etc)
• not consented to this trial